Safety of NBTXR3 Radioenhancer Delivery in Liver Metastases
B.D. Facer, É. Chajon, E Deutsch, Jessica M. Frakes(Moffitt Cancer Center), M. Pracht, Jeff Weiss, Omar I. Vivar(Nanobiotix (France)), V. Croisé-Laurent, T. De Baere, V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), D. Peiffert(Institut de Cancérologie de Lorraine), E. Rio, Ari J. Rosenberg(University of Chicago), Changyu Shen(Biogen (United States)), Yves Rolland(Université Toulouse III - Paul Sabatier), D Rolando(Nanobiotix (France)), J.J. Caudell(Moffitt Cancer Center), J. Durand Labrunie, J.-P. Bronowicki, Paul Tyan
International Journal of Radiation Oncology*Biology*Physics
September 27, 2024
Cited by 0
Related Papers
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines
|The journal of nutrition health & aging|2021|1.2k
The I.A.N.A. task force on frailty assessment of older people in clinical practice
|The journal of nutrition health & aging|2008|1.1k
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|431
Management of Malnutrition in Older Patients—Current Approaches, Evidence and Open Questions
|Journal of Clinical Medicine|2019|302